Effect of Low-Dose Aspirin in Preventing Early-Onset Preeclampsia in the Taiwanese Population—A Retrospective Cohort Study

Law, Kim-Seng; Wei, Tien-Yung

doi:10.2147/ijwh.s331213

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that the p38MAPK mRNA in the placenta of patients with preeclampsia is significantly higher than that in normal pregnant women, while the expression of p38MAPK in women with serious preeclampsia is higher than that in those having moderate preeclampsia. These data suggest that increased transcription and translation of the p38MAPK gene impair vascular endothelial growth factors and accelerate apoptosis of extravillous trophoblasts, thereby affecting the infiltration capacity of the trophoblasts and inducing preeclampsia [18]. At present, there are limited studies on the effect of aspirin on the p38MAPK signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

Aspirin protects against preeclampsia via p38MAPK signaling pathway

Su¹,

Zhou²,

Zhen³

et al. 2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the protective effect of aspirin against preeclampsia and the involvement of p38MAPK signaling pathway in the process.Methods: Sixty pregnant women who underwent antenatal care and delivery at Chancheng Central Hospital from September 2020 to September 2022 were selected and equally assigned to control group (CG) and experimental group (EG). From the 12th week of gestation, EG was administered 100 mg of aspirin and 1000 mg of calcium carbonate daily, while CG was given only 1000 mg of calcium carbonate daily. Both groups were treated up to the 35th week of gestation. Thereafter, blood samples were taken for measurement of serum levels of p38MAPK. In addition, the blood pressure of the women was measured. The incidence of preeclampsia and maternal-infant outcomes were assessed.Results: EG had a lower p38MAPK level at week 35 of pregnancy, and lower blood pressure levels at the 27th and 35th weeks of gestation, than CG (p < 0.05). There were 5 cases of preeclampsia (16.7 %) in EG, and 13 cases (43.3 %) of preeclampsia in CG, with a lower incidence of preeclampsia in EG than in CG (ꭓ2 = 5.079, p < 0.05). The numbers of newborns through premature delivery and cesarean section, as well as Apgar score ≤ 7 were lower in EG than in CG (p < 0.05).Conclusion: Aspirin exerts a protective effect against preeclampsia through via p38MAPK signaling pathway. Therefore, aspirin treatment may be useful in reducing the incidence of preeclampsia and improving maternal-infant outcomes. However, further clinical trials are recommended prior to application in clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%